Sophie C. McGrath

• Advised Quanta Dialysis Technologies Limited, a medical device company focused on haemodialysis systems for use in the clinic and home, on the first closing of its series C funding round raising over £38 million.
• Advised N+1 Singer as nominated adviser and broker to Verona Pharma plc, a listed drug development company, in relation to its £44.7 million UK and U.S. placing.*
• Advised a listed life sciences company in relation to its acquisition of a medical devices business based in the U.S.*
• Advised Cruncher Technologies Limited, a company using artificial intelligence to solve big data issues for the financial markets, on various financing rounds and its commercialisation into the U.S.*
• Advised Neuroprotexeon Limited, a late clinical-stage pharmaceutical and medical device company, on its initial spinout from Imperial College London, subsequent rounds of private financing and issues relating to the cross border nature of its operations.*
• Advised Gilde Healthcare Partners B.V. as lead investor on multiple financing rounds into Qinec Limited, a digital healthcare company.*
• Advised Mustard Seed, an impact investment fund, on multiple investments including:*
  • Skin Healthcare, a skin analytics app and device designed to help identify early signs of skin cancer
  • Beulah, a luxury goods company providing employment opportunities to victims of human trafficking
  • Switchee, a company seeking to significantly reduce energy use and spending
• Advised Novo A/S, Lundbeckfond A/S and Gilde Heathcare Partners B.V. on multiple financing rounds into Acacia Pharma Limited, a specialty pharmaceutical company focused on the development and commercialisation of new treatments for the conditions arising as a consequence of surgery, cancer or cancer treatment.*
• Advised Arc Medical Limited, a UK medical devices company, on a partial exit by certain shareholders to Norgine Ventures, along with a strategic investment and working capital facility from Norgine.*
• Advised EQ Investors, a B Corporation certified wealth manager (B Corporations are for-profit companies certified as meeting rigorous standards of social and environmental performance, accountability, and transparency), in relation to the acquisition of Truestone Wealth Management, a financial planning firm with £500 million of client assets under management.*
• Advised a European consortium of healthcare investors including Wellington Partners, Seroba Kernel, NBGI Ventures and B2V in relation to a £27 million Series B financing round into Quanta Fluid Solutions, a medical device company focused on haemodialysis systems for use in the clinic and home.*
• Advised Novo A/S on a €100 million investment in Symphogen A/S, a Danish biotech company that specialises in the development of recombinant antibody therapies for the treatment and prevention of disease.*

* Denotes experience prior to joining Goodwin.